Resistance Training and Cardiometabolic Health
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03325933 |
Recruitment Status :
Terminated
(COVID-19)
First Posted : October 30, 2017
Last Update Posted : April 19, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Insulin Sensitivity Endothelial Dysfunction Blood Pressure | Other: High Load/Low Rep Resistance Training Other: Low Load/High Rep Resistance Training | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 62 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Prevention |
Official Title: | Resistance Training and Cardiometabolic Health |
Actual Study Start Date : | September 21, 2017 |
Actual Primary Completion Date : | August 31, 2020 |
Actual Study Completion Date : | August 31, 2020 |
Arm | Intervention/treatment |
---|---|
Experimental: Resistance Training 1
Participants will perform resistance training with high training loads and low repetitions (high load/low rep resistance training).
|
Other: High Load/Low Rep Resistance Training
Participants will be prescribed High Load/Low Rep resistance training. |
Experimental: Resistance Training 2
Participants will perform resistance training with low training loads and high repetitions (Low load/high rep resistance training).
|
Other: Low Load/High Rep Resistance Training
Participants will be prescribed Low Load/High Rep resistance training. |
No Intervention: Wait-list control
This group will be offered the option of participating in either experimental group after the study is completed.
|
- Arterial Stiffness [ Time Frame: Change from Baseline Pulse Wave Velocity at 12 weeks ]Measured via pulse wave velocity
- Insulin Sensitivity [ Time Frame: Change from Baseline Matsuda Index at 12 weeks ]Measured via oral glucose tolerance testing (OGTT)
- Endothelial Function [ Time Frame: Change from Baseline %FMD at 12 weeks ]Measured via flow mediated dilation (FMD)
- Cardiac echocardiography [ Time Frame: Changes in systolic and diastolic parameters from baseline to 12 weeks ]Measured using ultrasound
- Isokinetic Strength [ Time Frame: Change from Baseline isokinetic strength at 12 weeks ]Measured via dynamometry
- Isometric Strength [ Time Frame: Change from Baseline Isometric strength at 12 weeks ]Measured via dynamometry
- Hexokinase [ Time Frame: Change from Baseline in insulin signalling proteins at 12 weeks ]Measured via skeletal muscle biopsies
- Insulin signaling proteins [ Time Frame: Change from Baseline in insulin signaling proteins at 12 weeks ]Measured via skeletal muscle biopsies
- Muscle Volume [ Time Frame: Change from Baseline Muscle Volume at 12 weeks ]Measured via ultrasonography
- Body Composition [ Time Frame: Change from Baseline body composition at 12 weeks ]Measured via Dual X-Ray Absorptiometry (DXA)
- Central Systolic Pressure [ Time Frame: Change from Baseline Central Systolic Pressure at 12 weeks ]Measured via Pulse Wave Analysis
- Central Diastolic Pressure [ Time Frame: Change from Baseline Central Systolic Pressure at 12 weeks ]Measured via Pulse Wave Analysis
- Maximal Oxygen Consumption [ Time Frame: Change from Baseline VO2peak at 12 weeks ]Measured via VO2peak testing using an integrated metabolic system.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 55 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Male and female
- 18-55 years of age
- BMI 25-40
- No recent history of starting a structured exercise program or diet in the last 3 months
Exclusion Criteria:
- Current smoker and/or recreational drug user
- Answers "yes" to one or more questions on the Physical Activity Readiness Questionnaire
- Diagnosed diabetes, heart disease
- History of anabolic steroid use in the past six months
- Taking medications for treatment of diabetes, heart disease, and hypertension.
- Orthopedic or musculoskeletal contraindications to resistance training
- Unwilling to follow any aspect of the study protocol including blood sampling and weight training

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03325933
United States, Arizona | |
Arizona State University | |
Phoenix, Arizona, United States, 85004 |
Principal Investigator: | Siddhartha S Angadi, PhD | Arizona State University |
Responsible Party: | Siddhartha Angadi, Assistant Professor, Arizona State University |
ClinicalTrials.gov Identifier: | NCT03325933 |
Other Study ID Numbers: |
STUDY00006617 |
First Posted: | October 30, 2017 Key Record Dates |
Last Update Posted: | April 19, 2021 |
Last Verified: | April 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | This data will be used primarily for a doctoral dissertation project as well as manuscript publication. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
insulin sensitivity muscle strength resistance training |
strength training vascular function arterial stiffness glucose tolerance |
Insulin Resistance Hypersensitivity Immune System Diseases |
Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases |